Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background Rituximab-based immunochemotherapy has improved outcomes in patients
with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal …

Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Background Mantle-cell lymphoma is generally incurable. Despite high rates of complete
response after initial immunochemotherapy followed by autologous stem-cell …

Background Rituximab plus chemotherapy has been shown to be effective in patients with
advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …